EP0371041A1 - Procede de preparation d'une proteine ou d'un polypeptide, sequence d'adn codant pour le polypeptide, microorganisme contenant la sequence d'adn et le polypeptide et utilisation du polypeptide comme preparation pharmaceutique - Google Patents

Procede de preparation d'une proteine ou d'un polypeptide, sequence d'adn codant pour le polypeptide, microorganisme contenant la sequence d'adn et le polypeptide et utilisation du polypeptide comme preparation pharmaceutique

Info

Publication number
EP0371041A1
EP0371041A1 EP88905733A EP88905733A EP0371041A1 EP 0371041 A1 EP0371041 A1 EP 0371041A1 EP 88905733 A EP88905733 A EP 88905733A EP 88905733 A EP88905733 A EP 88905733A EP 0371041 A1 EP0371041 A1 EP 0371041A1
Authority
EP
European Patent Office
Prior art keywords
polypeptide
amino
dna sequence
glu
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP88905733A
Other languages
German (de)
English (en)
Inventor
Henrik Dalb Ge
Jens M Lvig
Kim Ry Hejn S
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK320987A external-priority patent/DK320987D0/da
Priority claimed from DK177488A external-priority patent/DK177488A/da
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of EP0371041A1 publication Critical patent/EP0371041A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Definitions

  • the present invention concerns a process for preparing a protein or polypeptide which contains an amino-terminal extension, preferably with at least two amino acids, in addition to the desired polypeptide chain.
  • proteins or polypeptides may be produced biosynthe ically by cultivating a host organism which contains a vector with the DNA sequence, such as a plasmid, which codes for the desired polypeptide.
  • the resulting polypeptide is isolated from the cultivation medium and purified, e.g. chromato- graphically.
  • polypeptides that are produced biosynthetically in this way are so atostatin , insulin and human growth hormone.
  • Another advantag . e of transport of the desired protein out into the periplasma is that the protein here folds sub ⁇ stantially correctly to provide the native protein with the correct folding for the active protein. This involves essential advantages in the biosynthetic production of proteins on an industrial scale because then it is not necessary to effect subsequent folding, which is very difficult to perform in vitro.
  • the signal sequence is cut by an enzyme contained in the bacterium during or after the transport of the protein through the inner membrane. This cut, however, is not completely specific since partially non-specific cutting of the signal sequence takes place depending upon the cultivation methods, strain of bacterium, etc., or sub- sequent enzymatic reactions occur, whereby the N-terminus of the desired protein is digested by peptidases in the periplas a to an uncontrolled degree.
  • a desired or mature protein by means of a microorganism coding for a desired protein with an amino terminal extension which comprises at least two amino acids, cf. the DK Patent Application 3448/84.
  • the desired protein with the extension is collected in the cytoplasma, from which it is to be isolated and purified.
  • the extension may be digested specifically to obtain the desired protein with a correct N-terminal in a pure state, using e.g. the enzyme DAP 1 and/or DAP 4.
  • S is a signal sequence
  • E is an amino extension with at least two amino acids, at least one of which is charged
  • P is the desired mature protein.
  • the desired polypeptide is synthetized with associated extension.
  • the signal sequence will cause the amino-terminal-extended protein to be transported through the membrane enclosing the cytoplasma
  • amino-terminal- extended polypeptide will occur in correctly folded form. If a microorganism with a periplasmatic space is used, the desired amino-extended polypeptide will normally be collected in it. It happens that under certain circum- ces, which are not fully understood, the protein also passes the outer membrane to the cultivation medium it ⁇ self.
  • the isolated amino-terminal-extended polypeptide can then be used as a substrate for e.g. the enzyme DAP 1 to produce the desired polypeptide, P.
  • the amino-terminal- extended polypeptide for production of the desired mature protein in a high yield and in a pure state by utilizing at the final purification the difference in charge between the mature protein and the amino-terminal- extended protein which might be left after the enzymatic cleavage.
  • the process of the invention can be used generally for preparation of an arbitrary protein with an amino terminal extension which can be subsequently removed enzymatically .
  • proteins which can be produced by the process of the invention are amino-terminal-extended IGF 1, amino- terminal-extended 22K hGH, amino-terminal-extended 20K hGH, amino-terminal-extended IL 1 and amino-ter inal- ex ended insulin.
  • the amino terminal extension, E. preferably comprises 2 amino acids, as mentioned, and in particular preferably 4 to 16 amino acids.
  • the amino terminal extension contains at least one charged amino acid.
  • the presence of one or more charged amino acids permits effective purification and isolation of the desired protein by chromatography .
  • the invention also concerns a DNA sequence, a plasmid containing this DNA sequence, and microorganisms in which such a plasmid has been inserted.
  • any microorganism into which a plasmid may be inserted can be used in the process of the invention.
  • E. coli lends itself particularly well for the purpose, but also other microorganisms may be used.
  • An example of this is B. subtilis.
  • This microorganism does not, as is the case with E. coli, have an outer membrane and accordingly a periplasmatic space.
  • the resulting polypeptide is transported through the cell membrane and out into the cultivation medium with simultaneous cutting of the signal sequence.
  • the polypeptide will be correctly folded and can be isolated from the cultivation medium in a manner known per se, cf. by chromatography on an ion-exchange resin.
  • the polypeptide produced by the process of the invention which comprises the amino-terminal extension, is suitable as a starting material in the preparation of the mature protein, P.
  • the amino terminal extension in a suitable manner, it is possible to obtain specific enzymatic digestion of the extension.
  • one of the enzymes DAP 1 or DAP 4 may be used for this pur ⁇ pose, which causes stepwise cleavage of the extension, preferably by removal of two amino acids at a time, followed by isolation of the resulting mature protein from possibly non-reacted or partially reacted, extended polypeptide in a known manner, such as by chromatography.
  • the invention moreover concerns an amino-terminal-extended interleukin 1 (IL-1) as well as a preparation containing the biologically active polypeptide.
  • IL-1 interleukin 1
  • Interleukin 1 is a polypeptide which is produced in various animal cells, such as monocytes.
  • the full amino acid sequence of IL-1 and the precursor of IL-1 are known.
  • IL-1 has various biological effects. Thus, it was shown recently that IL-1 has a cytotoxic effect on the Langer- hans's islets, i.e. /.-cells in the pancreas, and may thus cause insulin dependent diabetes ellitus (IDDM). The effect occurs in connection with the binding of IL-1 to specific receptors of the /3-cells.
  • IDDM insulin dependent diabetes ellitus
  • IL-1 The production of excess of IL-1 can take place by various biological influences.
  • This embodiment of the invention is based on the finding that amino-terminal-extended IL-1 counteracts the cyto ⁇ toxic effect of IL-1, such as against .-cells in the pancreas.
  • Amino-terminal-extended IL—1 is believed to bind to the same receptors as IL-1 on the - c e l l s and thus block these receptors. This would prevent the cytotoxic effect of IL-1.
  • the present invention also concerns amino-terminal- extended IL-1. Further, the invention concerns prepa ⁇ rations containing amino-terminal-extended IL-1, which may e.g. be used for therapeutic or prophylactic treat ⁇ ment of IDDM.
  • the invention moreover concerns a DNA-strueture coding for amino-terminal-extended IL-1 or amino-terminal- extended IL-1 derivatives.
  • the extension of the IL-1 and IL-1 derivatives may have different lengths and e.g. compris * e most of the pre- sequence of the naturally occurring IL-1. Preferably, however, a considerably shorter amino terminal extension is used, e.g. comprising 2 to 6 amino acids.
  • polypeptides of the present type are amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids
  • the polypeptide may be modified in a manner known per se or be amended, e.g. by replacing one or more amino acids by other amino acids or by removal of one or more amino acids in the C-terminus.
  • the polypeptide of the invention can be used therapeutic- ally for combatting or preventing i.a. diabetes and autoimmune diseases. It is also proposed to use the poly ⁇ peptide for treatment of patients who are subjected to septic shock under the action of endotoxiantibodies.
  • pharmaceutical preparations in particular injectable preparations are used, containing the poly ⁇ peptide in a pharmaceutically acceptable carrier medium.
  • the present polypeptide is produced biosynthetically by cultivation of a microorganism or a cell line which contains a gene coding for the polypeptide, which is then recovered, purified and processed to the desired preparation.
  • the restriction sites EcoRI/BamHI have inserted between them a DNA segment containing a promotor, a Shine Dalgarno sequence and the signal sequence from outer membrane protein A (2), followed by a synthetic DNA linker containing the recognition sequence for the restriction enzymes Narl, Bglll, PvuII and Ba HI.
  • the plasmid pHD167 is likewise a derivative of the plasmid pAT153.
  • This plasmid contains a promotor, a Shine Dalgarno sequence, a synthetic gene coding for IGF1, and a transcription terminator.
  • the above-mentioned sequences are inserted between the EcoRI and BamHI restriction sites in pAT153.
  • the plasmid pHD176 contains the plasmid region, the promotor region and the signal sequence from the plasmid pHD165 as well as the transcription terminator and the gene for IGF1 from the plasmid pHD167, isolated as an Ace III/BamHI DNA fragment, and a small synthetic DNA linker coding for amino terminal excusion.
  • the plasmid pHD176 contains the coding region for the outer membrane protein A signal sequence, followed by the amino terminal extension Ala-Glu-Ala-Glu, and the coding sequence for IGF1.
  • the plasmid pHD141 shown in fig. 2 is a derivative of the plasmid pHD167 in which the coding sequence for IGF1 has been replaced by the coding sequence for amino-terminal- extended 20K-hGH.
  • the plasmid pHD223 contains the sequences contained in the plasmid pHD141 between Clal/EcoRI, a Clal/Narl DNA fragment coding for the signal sequence from pHD165 as well as a synthetic DNA linker coding for an amino terminal excusion.
  • the plasmid pHD223 thus contains the coding region for the outher membrane protein A signal sequence, followed by the amino terminal extension Ala-Glu-Ala-Glu , followed by the coding sequence for 20K-hGH.
  • the plasmid pHD106-9 shown in fig. 3 is a derivative of the vector pUC18 into which the coding region for the signal sequence from E. coli fimbria protein K88 (3) has been inserted between the restriction sites BamHI/Pstl.
  • the plasmid pHD117-4 SP13 is a derivative of the plasmid pHD167, in which the coding region for IGF1 has been replaced by the coding region for amino-terminal-extended 22K-hGH.
  • the plasmid pHD148-22K-hGH contains the signal sequence from the fimbria protein K88, followed by the amino terminal extension Ala-Glu-Ala-Glu-Ala-Glu, followed by the coding region for 22K-hGH.
  • the plasmid pHD163 shown in fig. 4 is a derivative of the plasmid pHD167 in which the coding region for IGF1 has been replaced by the coding region for amino-terminal- extended IL-1.
  • the plasmid pHD185 is a derivative of the plasmid pAT153, into which a synthetic DNA fragment containing the coding region for the outer membrane protein A signal sequence as well- as the recognition sites for the restriction enzymes Narl, Bglll, PuvII and BamHI have been inserted between the restriction sites EcoRI/BamHI.
  • the plasmid pHD163/185 thus contains the coding region for the signal sequence from the outer membrane protein A, followed by the amino terminal extension Met-Glu-Ala-Glu- Phe-Asp and the coding region for interleukin 1.
  • the plasmid pHD165 which contains a promotor and the above-mentioned signal sequence was cut with the enzymes Narl/Ba HI, and then the plasmid fragment was purified.
  • the plasmid pHD167 containing e.g. the coding sequence for human IGF1 followed by transcription terminator, was cut with the enzymes AccI I I/BamHI , and then a fragment of about 600 base pairs was purified. These two fragments as well as a synthetic DNA linker, containing a restriction overhang for the enzymes Narl/AccIII (coding for amino terminal extension) were then ligated together to form the plasmid pHD176.
  • the ligation mixture was subsequently transformed into the bacterium E. coli MC1061, plated on ampicillin containing aga plates and incubated overnight at 37 °C.
  • a plurality of bacteria colonies was selected and cultivated for further characterization by restriction enzyme analysis.
  • the clones pHD176-D, -F were then selected.
  • the clone pHD176-F was cultivated on a large scale, and then the bacteria were harvested by centri- fugation.
  • the bacteria were then partly exploded by means of osmotic shock, so that the proteins present in the periplasma were released from the bacteria.
  • the amino-terminal- extended IGF1 was purified. This material was then used as a substrate for DAP 1, whereby the N-terminal extension was specifically removed.
  • the expression level in the above-mentioned cultivation of the bacterium HD176-F was about 5 mg of amino-terminal- extended IGF1 per litre of bacteria culture with an 0D600 of about 1.
  • the plasmid pHD141 containing the gene for 20K human growth hormone, was cut with the enzymes Clal/EcoRI, and then the plasmid fragment was purified.
  • the plasmid pHD165 was cut with the enzymes Clal/Narl, and then a fragment of about 120 base pairs was purified. These fragments were subsequently ligated together in the presence" of a synthetic DNA linker with an overhang for the restriction enzymes Narl/EcoRI to form the plasmid pHD223.
  • the ligation mixture was transformed into E. coli MC1.061 and plated on ampicillin containing growth plates
  • the expression level was of the same order as mentioned in example 1.
  • the plasmid pHD106-9 which contains another signal sequence described above, was cut with the restriction enzymes BamHI/Hindlll . A fragment of 190 base pairs was then purified. This fragment was subsequently cut with the enzyme BstNI, treated with SI nuclease to produce a blunt end, phenol-extract ⁇ d, ethanol-precipitated, and then cut with the enzyme Clal. A fragment of 60 base pairs was then purified.
  • the plasmid pHD117-4 SP13 was cut with the enzymes Clal/EcoRIj and then the plasmid fragment was purified. The two mentioned purified fragments were ligated together in the presence of a BstNI/EcoRI linker to form the plasmid pHD148-22K-hGH.
  • the ligation mixture was transformed into the bacterium E. coli MC1061 and plated on ampicillin containing growth plates. After incubation overnight, a plurality of colonies was selected for further character- ization by restriction enzyme analysis and DNA sequence determination. Cultivation and isolation of the resulting amino-terminal- extended 22K hGH were performed in the same manner as stated in example 1.
  • the plasmid pHD185 containing the coding sequence for a signal sequence, was cut with the enzymes Clal/Narl, and then a DNA fragment of about 90 base pairs was purified. These two fragments were then ligated together to form the plasmid pHD163/185.
  • the obtained plasmid was inserted into E. coli, which was cultivated in the usual manner.
  • the resulting amino- terminal-extended human IL-1 was purified and converted into human IL-1 by reaction with DPA 1.
  • a gene coding for the amino acids 117-269 in the IL-1 precursor was produced. It has been found by comparative studies of messenger RNA sequences of high-level- expressed and low-level-expressed genes in bacteria, respectively, that there is a strong correlation between codon use and expression efficiency. Accordingly, it was decided to use the codons which are most frequently used in high-level-expressed E. coli genes. Useful cloning sites were inserted inside the gene as well as at both ends. The gene was extended with a DNA sequence which codes for the amino terminal extension Met-Glu-Ala-Glu (MEAE). The gene was produced by stepwise cloning between restriction sites of oligonucleotides having an average length of 80 to 100 nucleotides. The sequence of the gene for MEAE-IL-1 is shown in fig. 5.
  • E. coli was selected as the host organism since glyco- sylation or other modifications of IL-1 have not been reported.
  • the expression was controlled by a synthetic promotor (SP13) and an .optimum Shine Dalgarno sequence.
  • SP13 synthetic promotor
  • the used promotor was selected because it is known that it is effective for expression of e.g. bhGH in E. coli (up to 20 ⁇ of total bacteria protein) (Bio Technology,
  • IL-1 Extraction of IL-1 was performed as described in Bio Technology, Vol. 4, Dec. 1986, p. 1078. Purification of the N-terminal-extended IL-l- derivatives was performed on FF-S sepharose, FF-Q sepharose and gel filtration colonies, respec i ely. The derivatives in question were characterized by amino acid analyses, N-terminal sequence analysis, molecular weight determination by the firm atomic bombardment method (Barber M. et al.; (1981) J. Chem. Soc., Chem. Comm. Vol. 1981, p. 325-327), SDS and native electrophoresis.
  • a DNA segment with the coding region for pheny1-alanine-aspartic acid was inserted into the clone pHD230. It was inserted in such a manner that IL-1 was extended with the sequence Met- Glu-Ala-Glu-Phe-Asp- .
  • the gene for amino-terminal- extended IL-1 was expressed in E. coli and purified as described above.
  • the clone was prepared by in vitro mutagenesis on the plasmid pHD230.
  • the amino-terminal-extended IL-1 was expressed and purified as described above.
  • the N-terminal methionine group was cleaved in vivo by an E. coli enzyme Example 10
  • the resulting clone pHD228 was then cut with the enzymes Narl/Clal, and then a fragment coding for the below amino acid sequence was inserted.
  • the gene was expressed in E. coli and purified as described above.
  • the inserted amino acid sequence had the following composition:
  • the specific bioactivity (units/ng IL-1-3) is determined by simultaneous measurement of the biological response in the comitogenic mouse thymocyte profileration assay (LAF) and by quantization by means of IL-l-/_ Elisa of the corresponding amount of IL-1-3 protein.
  • LAF assay is performed as described above (Scand. 3. Immunol. 26:611, 1987, Scand. J. Immunol. : Endotoxin stimulated human onocyte secretion of interleukin 1, tumor necrosis factor alpha and prostaglandin E show stable in erindi idual difference, in press).
  • Thymocytes are isolated from 5 to 7 weeks old male mice of the C3H/he mice strain (Charles River, Federal Republic of Germany). After washing of the cells, these are plated in shallow microtiter plates (Nunc, Roskilde) in a medium consisting of a mixture of 90? ⁇ RpMI-164 and 10? ⁇ ac ⁇ cumulated heat inactivated human serum, the medium having been added to the sample in a dilution series beginning with 20 vol? ⁇ and diluted 1:2 in up to 8 steps. The test series is repeated 3 times. PHA (Difco) 5 ,ug/ml is added to each well. After 48 hours' incubation at 37 °C 1 ,uCi tritiated thy idin is added per well. The cultures are harvested on glass fibre filters (Skatron, Norway) after another 18 hours' incubation by means of a semi-automatic cell culture harvester. Then the filters are counted in a beta counter.
  • the results are calculated as follows: The average of triplicates is calculated. Linear regression is performed for each dilution series, comprising a count above 3 x background. The highest counts in the dilution series are included only if they are more than 10? ⁇ higher than the count in the next dilution step. Linear regression is performed either semi-logarithmlcly or double-logarith- micly. This results in parallel linear curves which directly allow quantization of the biological response with respect to a standard consisting of recombl ⁇ ant I -l- 100 ng/ml (WHO standard). The results can then be stated in Units/ml, the WHO standard containing 100 U/ng.
  • IL-1-5 Elisa is performed according a standardized Elisa method (Cistro ⁇ ).
  • Results appear from the enclosed table. It is noted that the specific activity of MEAE-IL-1-/3 is found to be 50 to 100 times weaker than recombinant full length IL-1-3. The results are obtained from 3 independent experiments.
  • the pancreas is removed from 5 to 7 days old rats of the Wistar strain, and the islets are isolated by collagenase degradation.
  • the islets are cultivated in RPMI-1640 + 10? ⁇ NCS at 37 °C in a moist atmosphere. After 1 week's incubation the islets are washed in RPMI-1640 + 0.5? ⁇ HS and incubated further for 6 days with and without IL-1.
  • the insulin secretion from the islets Is determined in Radioim unoassay (RIA).
  • RIA Radioim unoassay
  • Fig. 3 shows a standard curve for rIL-1. It will be seen that the insulin secretion is stimulated at very low rIL-1 concentrations (0.001 ng/ml) (about 130? ⁇ ), while the insulin secretion is inhibited to about 50? ⁇ at a somewhat higher concentration (0.1 ng/ml). References:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Une protéine ou un polypeptide représentés par la formule générale: E - P, où P représente un polypeptide mature désiré et E représente une extension de terminaison amino contenant de préférence au moins deux acides aminés, sont produits par culture d'une bactérie contenant une séquence d'ADN qui code pour un polypeptide représenté par la formule: S - E - P, où S représente une séquence de signaux et E et P représentent les mêmes éléments définis ci-dessus. L'extension de terminaison amino peut être extraite du polypeptide par digestion enzymatique, de façon à former la protéine ou le polypeptide matures, P, par exemple par utilisation de l'enzyme DAP 1. Le polypeptide peut être de l'interleukine 1 à extension de terminaison amino ou un dérivé de cette interleukine qui présente une activité biologique.
EP88905733A 1987-06-24 1988-06-23 Procede de preparation d'une proteine ou d'un polypeptide, sequence d'adn codant pour le polypeptide, microorganisme contenant la sequence d'adn et le polypeptide et utilisation du polypeptide comme preparation pharmaceutique Withdrawn EP0371041A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK320987A DK320987D0 (da) 1987-06-24 1987-06-24 Fremgangsmaade til fremstilling af et modent polypeptid med en nedspiselig amino-terminal ekstendering
DK3209/87 1987-06-24
DK1774/88 1988-03-30
DK177488A DK177488A (da) 1988-03-30 1988-03-30 Polypeptid og farmaceutisk praeparat indeholdende polypeptidet

Publications (1)

Publication Number Publication Date
EP0371041A1 true EP0371041A1 (fr) 1990-06-06

Family

ID=26066106

Family Applications (1)

Application Number Title Priority Date Filing Date
EP88905733A Withdrawn EP0371041A1 (fr) 1987-06-24 1988-06-23 Procede de preparation d'une proteine ou d'un polypeptide, sequence d'adn codant pour le polypeptide, microorganisme contenant la sequence d'adn et le polypeptide et utilisation du polypeptide comme preparation pharmaceutique

Country Status (5)

Country Link
EP (1) EP0371041A1 (fr)
JP (1) JPH03503596A (fr)
AU (1) AU1987088A (fr)
FI (1) FI896261A0 (fr)
WO (1) WO1988010299A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
DK470689A (da) * 1988-09-30 1990-03-31 Lilly Co Eli Hidtil ukendte dna-sekvenser, der koder for protein-derivater, som tillader hoej udtrykkelse af rekombinante proteiner med ringe molekylevaegt
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
US5158875A (en) * 1989-08-25 1992-10-27 Amgen Inc. Production of biologically active insulin-like growth factor i from high expression host cell systems
DK0527778T3 (da) * 1990-04-09 1996-10-21 Upjohn Co Forbedret fremgangsmåde til rensning af rekombinante proteiner og forbindelser, som er anvendelige ved en sådan fremgangsmåde
US5594115A (en) * 1990-04-09 1997-01-14 Pharmacia & Upjohn Company Process of purifying recombinant proteins and compounds useful in such process
DE69126434D1 (de) * 1990-08-20 1997-07-10 Novo Nordisk As Prozess für die Herstellung von biologisch aktivem IGF-1 durch Verwendung von amino-terminal verlängertem IGF-1
DE4105480A1 (de) * 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US5378613A (en) * 1991-09-24 1995-01-03 Eli Lilly And Company Method for increased expression of low molecular weight recombinant polypeptides
EP0587427B1 (fr) * 1992-09-09 1998-06-03 MITSUI TOATSU CHEMICALS, Inc. Procédé pour préparer l'hormone de croissance humaine
JPH10505502A (ja) * 1994-09-12 1998-06-02 シェーリング アクチェンゲゼルシャフト 修飾されたコラーゲン誘導血小板凝集阻害剤パリジピンの製法
GB9916630D0 (en) * 1999-07-16 1999-09-15 Univ Manchester Molecules derived from interleukins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8204811L (sv) * 1982-08-23 1984-02-24 Sven Lofdahl Dna-fragment innefattande en signalsekvens
EP0195680A3 (fr) * 1985-03-21 1987-06-10 Immunex Corporation Synthèse de protéines avec un peptide d'identification
FR2593518B1 (fr) * 1985-05-02 1989-09-08 Transgene Sa Vecteurs d'expression et de secretion de l'hirudine par les levures transformees
EP0206783A3 (fr) * 1985-06-20 1988-10-05 The Salk Institute Biotechnology Industrial Associates, Inc. Expression et secrétion de polypeptides à partir de Saccharomyces cerevisiae
DE3526995A1 (de) * 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8810299A1 *

Also Published As

Publication number Publication date
WO1988010299A1 (fr) 1988-12-29
AU1987088A (en) 1989-01-19
JPH03503596A (ja) 1991-08-15
FI896261A0 (fi) 1989-12-22

Similar Documents

Publication Publication Date Title
EP0518587B1 (fr) Proinsuline A-C-B, méthode de préparation, et d'utilisation, et intermédiaires dans la production d'insuline
EP0429586B1 (fr) Proteines de fusion pour hormones de croissance
EP0128733B1 (fr) Facteur de croissance humain semblable à l'insuline (IGF) préparé d'un hôte recombinant, procédé, vecteur d'expression et hôte recombinant pour cela, et composition pharmaceutique contenant de l'IGF
JP2566933B2 (ja) 真核細胞融合タンパク質、その生産及び用途、並びに方法
KR960016560B1 (ko) 인체 과립구 콜로니 자극인자 폴리펩타이드 유도체, 이를 코드화하는 dna, dna를 함유하는 재조합 플라스미드, 플라스미드를 함유하는 미생물 및 폴리펩타이드를 제조하는 방법
JP2665359B2 (ja) 免疫親和性による精製方法
US4745069A (en) Cloning vectors for expression of exogenous protein
US5362853A (en) Polypeptide derivatives of human granulocyte colony stimulating factor
AU638277B2 (en) Fusion proteins, their preparation and use
RU2198179C2 (ru) Модифицированный сигнальный пептид энтеротоксина - ii e. coli и микроорганизм, экспрессирующий белок слияния упомянутого пептида с гетерологичным белком
US20100210815A1 (en) Insulin production methods and pro-insulin constructs
US5681720A (en) DNA encoding human granulocyte colony stimulating factor plasmids and host cells comprising same, and methods of expressing the encoded polypeptide
JPH04503301A (ja) 合成インターロイキン―６
EP0371041A1 (fr) Procede de preparation d'une proteine ou d'un polypeptide, sequence d'adn codant pour le polypeptide, microorganisme contenant la sequence d'adn et le polypeptide et utilisation du polypeptide comme preparation pharmaceutique
JPH0759193B2 (ja) 外来性蛋白質発現用クロ−ニングベクタ−
EP0111389A2 (fr) Hormone de croissance porcine substantiellement pure, séquences d'ADN pour celle-ci et vecteurs d'expression et microorganismes transfectés pour la production de l'hormone de croissance porcine
HUT69963A (en) Non-naturally-occuring fusion proteins and process for preparing them
JPH0665318B2 (ja) ヒト成長ホルモンの製造方法
JP2506322B2 (ja) Ｇｒｆ前駆体をコ―ドするｄｎａ
JPS63263087A (ja) ポリペプチドの遺伝子工学的製造法
KR900001014B1 (ko) 소 성장 호르몬 유도체 발현 벡터의 제조방법
FI94867B (fi) Menetelmä granulosyytti-makrofaagi-pesäkkeitä stimuloivan tekijän puhdistamiseksi
EP0218652B1 (fr) Sequence d'adn
EP0361956A2 (fr) Expression augmentée de protéines recombinantes à faible poids moléculaire
JP2682738B2 (ja) 成長ホルモン融合蛋白質

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19891220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19910614

R18W Application withdrawn (corrected)

Effective date: 19910614